The acute inflammation induced by some therapies (e.g., recombination IFN, TLRs activator, STING activator) can redirect the pro-tumor TME toward an anti-tumor immune milieu, which can enhance efficiency of anti-cancer therapies (e.g., chemotherapy, radiotherapy and immunotherapy). The gene discussed is IFNA1; the disease is cancer.